Real-Life Clinical Use and Outcomes of Fusion Imaging-Guided Percutaneous Microwave Ablation of Hepatocellular Carcinoma: Experience from Two Italian Centers
Authors:
- Pierpaolo BiondettiPBPierpaolo Biondetti
- Francesco CicchettiFCFrancesco Cicchetti
- Gaetano Valerio Davide AmatoGAGaetano Valerio Davide Amato
- Velio AscentiVAVelio Ascenti
- Niccolò FinardiNFNiccolò Finardi
- Jacopo TintoriJTJacopo Tintori
- Francesco Ugo IovinoFIFrancesco Ugo Iovino
- Carolina LanzaCLCarolina Lanza
- Salvatore Alessio AngileriSASalvatore Alessio Angileri
- Pierluca TorciaPTPierluca Torcia
- Anna Maria IerardiAIAnna Maria Ierardi
- Giacomo VignatiGiacomo Vignati
Open Access
- 20 June 2025
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 15 (13) , 1573
Abstract
Background: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide. Percutaneous thermal ablation is an effective treatment, but standard ultrasound (US) guidance is limited in cases of inconspicuous nodules. Ultrasound fusion imaging (USFI), which overlays cross-sectional imaging onto real-time US is an emerging technique that improves tumor visibility and technical feasibility. This study reports real-life outcomes of USFI-guided microwave ablation (MWA) for HCC in two Italian centers. Materials and Methods: In this multicentric retrospective study, 56 patients with 73 poorly or non-visible HCC nodules underwent USFI-guided percutaneous MWA with no visibility or poor visibility on B-mode US. Technical success, complications, and local tumor control were evaluated, with follow-up imaging at 1 month and every 3 months thereafter. Results: Complete response (CR) at 1 month was observed in 78.1% of nodules, with residual disease (RD) more common in poorly visible nodules than non-visible nodules (18.1% vs. 4.2%, p = 0.019). During a median 13-month follow-up, local tumor progression (LTP) occurred in 9.6% of patients. No significant association was found with difficult tumor location. Conclusions: USFI-guided MWA is a safe and effective option for treating HCC nodules not adequately visualized with conventional US, expanding eligibility to complex cases.Keywords
All Related Versions
This publication has 23 references indexed in Scilit:
- Improved Outcomes of Thermal Ablation for Colorectal Liver Metastases: A 10-Year Analysis from the Prospective Amsterdam CORE Registry (AmCORE)CardioVascular and Interventional Radiology, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- CIRSE Standards of Practice on Thermal Ablation of Liver TumoursCardioVascular and Interventional Radiology, 2020
- Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancerJournal of Medical Ultrasonics, 2020
- Fusion Imaging and Virtual Navigation to Guide Percutaneous Thermal Ablation of Hepatocellular Carcinoma: A Review of the LiteratureCardioVascular and Interventional Radiology, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Cirse Quality Assurance Document and Standards for Classification of Complications: The Cirse Classification SystemCardioVascular and Interventional Radiology, 2017
- Real-time US-CT/MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinomaJournal of Hepatology, 2017
- Planning US for Percutaneous Radiofrequency Ablation of Small Hepatocellular Carcinomas (1–3 cm): Value of Fusion Imaging with Conventional US and CT/MR ImagesJournal of Vascular and Interventional Radiology, 2013
- Clinical Utility of Real-time Fusion Guidance for Biopsy and AblationJournal of Vascular and Interventional Radiology, 2011